Date: 2012-02-29
Type of information: Production agreement
Compound: ET-101
Company: Lonza (Switzerland) Eclipse Therapeutics (USA)
Therapeutic area: Cancer - Oncology
Type agreement: development
manufacturing
production
Action mechanism: ET-101 is a therapeutic antibody designed to target cancer stem cells.
Disease: cancer
Details: Lonza and Eclipse Therapeutics have announced an agreement for the production of Eclipse’s novel cancer therapeutic antibody, ET-101, using Light Path™ Development Services. ET-101 is under investigation for the inhibition of the growth of cancer stem cells. Under the agreement, Lonza will produce phase 1 clinical material at its development and manufacturing facility in Slough, UK.
Financial terms:
Latest news:
